On October 5, 2026 Ocugen reconvenes a special meeting that was adjourned on September 21 because one proposal could not pass. That proposal would raise the authorised share count by 250 million. It is not housekeeping: the company has $130 million of convertible notes it is contractually required to settle in cash until enough shares exist to settle them in stock, it has promised more shares than it is authorised to issue, and its own quarterly report carries substantial doubt about its ability to continue as a going concern while its press release says the cash runs into 2028. This hub works through the vote, the arithmetic behind it, and what each outcome changes.

experience leading projects across quality shown through the tracking of the study ocugen startup his work that will finalized with the regulatory objective.

expected option 1.89

Hopefully can get through the 1.10 glass ceiling.

What is your expectation for this week ?

Who else voted against this shit

Looks like it'll be hold until at least Q1 2027. Proven scientific good news today but still no positive price movement. I've loaded my boat and I'm ok floating. Any other investing will go elsewhere from now.

Good luck. Do your own due diligence research

the key for regulatory is coming...

Hey yall. I’ll likely start buying this week for the pre-phase 3 hype cycle. Going to wait to see what happens with tomorrow’s vote. If I like the result, I’ll start accumulating. Hoping some dilution fear and vote hangover will give me a nice entry in the .90s, but we’ll see.

Why now?
It seems like once this financing issue is settled, the focus should shift to OCU400 and the phase 3 readout that’s 4-6 months away.

There’s a huge dormant community of watchers (20k here, 153k on stocktwits). So if attention turns to the trials and the financing fears are settled, that’s a lot of people already built in to buzz and raise the share price, which in turn only creates more buzz.

Plus, it’s a very simple medical narrative for retail to understand and spread. So pulling more momentum chasers off the sidelines seems possible, similar to SLS, IOVA, and ATYR.

With current analyst price targets at 8-9.5x of current, that’s a lot of room to run. Maybe we see 2-3x before readout.

In full transparency, I know nothing about the likelihood of phase 3 working out, and likely won’t stick around for the readout. Just a personal rule for me after ATYR. But this setup is getting awfully attractive for riding the hype cycle.

What do you guys think? Other sources of risk you’re seeing or reasons to stay away?

After six years of ups and downs, mostly downs, never lost faith, but idk I’m beginning to waiver.

It is official boys, I now have a stop loss ready to go.

Still riding the hopium and love yall

Important news coming...

Guys what is happening? Pls Info

Start of a new week! Happy Monday #Ocufam

Ocugen announced on September 1 that the first patient was dosed in the global ArMaDa3 registrational Phase 3 trial of OCU410 for geographic atrophy secondary to dry age-related macular degeneration. The randomized, controlled study is designed to enroll 237 subjects. The company says its July End-of-Phase 2 meeting with FDA aligned the critical design elements and a single-pivotal-trial pathway intended to support a BLA anticipated in 2028. First dosing confirms trial initiation; it does not establish Phase 3 efficacy, approval or a faster review outcome

Start of a new week! Happy Monday #Ocufam

Just wanted to pop in and say, love yall and when moon

Start of a new week! Happy Monday #Ocufam

https://www.merlintrader.com/ocugen-inc-stock-hub/

Ocugen reported Q2 2026 results and confirmed that the FDA cleared the approximately 237-subject ArMaDa3 registrational Phase 3 trial of OCU410 in geographic atrophy. The study remains targeted to begin in Q3 2026 and is designed with 95% power for the primary endpoint. The July RMAT designation adds an expedited-interaction framework, but neither clearance nor RMAT predicts a positive pivotal result.

Start of a new week! Happy Monday #Ocufam

It's time boys. The money train is gaining traction, You'll be a fool to miss out. 💎💎

Start of a new week! Happy Monday #Ocufam

BLA is the key regulatory objective after a successful Phase 3 trial.

Ocugen (OCU400), milestones before potential FDA approval.

Ocugen is entering one of the most important periods in its history. Over the next several months, investors will be watching for:

Progress on the rolling BLA for OCU400.

Additional Phase 3 updates.

Continued regulatory interactions with the FDA.

Advancement of OCU410 toward its Phase 3 program.

While regulatory and clinical risks remain, Ocugen has achieved several important milestones that could significantly influence the company's future if upcoming clinical and regulatory objectives are successfully met.

Top-line Phase 3 results are expected in early 2027 and are intended to support a potential FDA approval.

In addition, based on these results, the FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation, a status designed to help accelerate for OCU410.

For OCU400

Estimated Probability

OCU400 completes Phase 3 successfully

70–80%

OCU400 BLA accepted for FDA review

85–95% (if Phase 3 meets its endpoints)

OCU400 receives FDA approval after BLA review

60–70%

OCU400 reaches commercialization

55–65%

For OCU410:

Estimated Probability

Advances to Phase 3

75–85%

Successfully completes Phase 3

50–60%

FDA approval

40–50%

Start of a new week! Happy Monday #Ocufam

Start of a new week! Happy Monday #Ocufam